For the quarter ending 2026-03-31, BICX had $72,551 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -859,892 | -471,218 | -808,505 | -2,229,040 |
| Change in fair value of royalty liability | - | - | - | -31,324 |
| Depreciation and amortization | 11,195 | -124,804 | 168,807 | - |
| Amortization of discount on royalty obligation | 115,334 | 121,774 | 121,774 | 233,888 |
| Fair value of options issued | - | - | 81,874 | - |
| Amortization of debt discount | 0 | 1,877 | 53,861 | - |
| Other income | - | 0 | 0 | 0 |
| Impairment of intellectual property | 6,374 | - | - | - |
| Amortization of right-of-use asset | 10,524 | 10,315 | 10,112 | 19,629 |
| Loss on settlement of debt | -100,000 | 0 | 0 | -187,514 |
| Change in fair value of upfront purchase price liability | 0 | 747 | 1,785 | 4,894 |
| Change in fair value of royalty liability | 0 | -310,835 | 31,324 | - |
| Stock based compensation | 108,375 | 351,258 | -65,813 | 307,159 |
| Deposits | - | 0 | 0 | 0 |
| Imputed interest for related party advances | 15,236 | 8,309 | 9,253 | 18,814 |
| Deferred revenue | - | 0 | 0 | 0 |
| Warrants issued in connection with the sales representative agreement | - | 4,430 | - | - |
| Accounts receivable | 76,889 | 59,017 | 143,200 | 51,242 |
| Grant receivable | 69,694 | 813,541 | -915,243 | 153,728 |
| Inventory | - | 9,828 | - | - |
| Prepaid expenses | -13,388 | -1,064 | -13,880 | 47,081 |
| Depreciation and amortization | - | - | - | 96,820 |
| Accounts payable and accrued expenses | 253,990 | -1,532,259 | 868,743 | 950,355 |
| Amortization of debt discount | - | - | - | 52,522 |
| Royalty liability | 7,886 | - | - | - |
| Upfront purchase price liability | -42,503 | -43,684 | -158,007 | -155,673 |
| Deferred revenue, grant | - | -56,590 | - | - |
| Lease liability | -10,523 | -10,316 | -10,112 | -19,629 |
| Net cash used in operating activities | -432,971 | -847,722 | -634,447 | -816,122 |
| Payment to eidl loan | - | - | 1,226 | - |
| Payment of notes payable | - | 150,000 | - | - |
| Proceeds from sale of common stock | - | - | 15,750 | - |
| Proceeds from notes payable | - | 0 | 0 | 0 |
| Proceeds from common stock subscription and royalty agreement | 500,000 | 1,179,110 | 700,000 | - |
| Payment to economic injury disaster loan | -382 | 753 | - | 739 |
| Payment of notes payable - related party | 5,000 | 518,700 | 0 | 7,000 |
| Proceeds from notes payable | 75,000 | - | - | - |
| Proceeds from notes payable - related party | 85,904 | 205,000 | 95,000 | 847,700 |
| Net cash provided by financing activities | 505,522 | 699,394 | 810,263 | 839,961 |
| Net increase (decrease) in cash | 72,551 | -148,328 | 175,816 | 23,839 |
| Cash, beginning of period | 139,360 | 287,688 | 88,033 | - |
| Cash, end of period | 211,911 | 139,360 | 287,688 | - |
BioCorRx Inc. (BICX)
BioCorRx Inc. (BICX)